Glenmark’s Carvedilol Blood Pressure Drug Contaminated with Probable Carcinogen, Class Action Lawsuit Alleges

Glenmark Pharmaceuticals is facing a major 139-page proposed class action lawsuit alleging that the company manufactured and sold generic Carvedilol blood pressure medication contaminated with a probable human carcinogen. Filed in federal court, the suit claims the generic beta-blocker lacked the safety, purity, and quality promised to patients, rendering the prescription pills adulterated, misbranded, and legally worthless. If you or a loved one paid for or took Glenmark’s generic Carvedilol to manage high blood pressure or heart failure, you may be eligible to join the legal effort to hold the pharmaceutical maker accountable.

Why Glenmark’s Generic Beta-Blocker Faces a Federal Class Action Lawsuit

Carvedilol is a widely prescribed beta-blocker commonly used to treat hypertension (high blood pressure), manage heart failure, and improve survival rates following a heart attack. Marketed as a therapeutically equivalent generic alternative to the brand-name drug Coreg, Glenmark’s generic version was required by federal law to meet strict quality and safety standards.

However, the 139-page class action complaint alleges that Glenmark failed to maintain the same safety profile, strength, and purity as the brand-name counterpart. According to court filings, the generic medication contained undisclosed levels of N-Nitroso-Carvedilol I, a nitrosamine impurity classified by health authorities as a probable human carcinogen. Plaintiffs assert that because of this chemical contamination, the medication was unfit for consumption and poses serious health risks to everyday consumers who relied on it daily to protect their cardiovascular health.

How Nitrosamine Contamination and Manufacturing Failures Compromised Patient Safety

Nitrosamines are chemical compounds commonly found at low levels in water and foods, but chronic exposure to elevated levels can increase the risk of developing cancer. According to the lawsuit, the U.S. Food and Drug Administration (FDA) initiated nationwide recalls covering hundreds of thousands of bottles of Glenmark’s Carvedilol after testing revealed nitrosamine levels exceeding allowable safety limits.

The lawsuit highlights that Glenmark attributed the contamination to its own internal failure to control nitrite levels in the excipients (inactive ingredients) used during the drug manufacturing process. The complaint charges that these quality assurance and testing breakdowns represent a direct violation of federal current Good Manufacturing Practices (cGMP). Because these manufacturing failures affected the production process itself, the lawsuit argues that the generic Carvedilol was legally adulterated and unsellable—regardless of whether a specific pill within a bottle contained the chemical impurity.

Understanding Federal Good Manufacturing Practices and Drug Adulteration Laws

Under the Federal Food, Drug, and Cosmetic Act (FDCA), prescription medications sold in the United States must strictly comply with current Good Manufacturing Practices (cGMP). These federal regulations establish mandatory baseline standards for the design, monitoring, control, and maintenance of manufacturing processes and facilities.

When a drug manufacturer fails to adhere to cGMP standards, any pharmaceutical produced under those conditions is legally deemed “adulterated” and “misbranded.” Selling adulterated drugs breaches state consumer protection laws and implied warranties of merchantability. Class action lawsuits serve as an essential tool for everyday patients, empowering consumers to pool their claims and demand financial justice when pharmaceutical giants fail to uphold mandatory safety controls.

Who May Be Eligible to Join the Glenmark Carvedilol Lawsuit

You may be eligible to participate in this legal action if you purchased or ingested generic Carvedilol manufactured by Glenmark Pharmaceuticals to treat high blood pressure, heart failure, or related cardiac conditions.

The lawsuit asserts that patients would not have bought the generic medication—or would have paid significantly less for it—had they been warned that the pills were manufactured in violation of cGMP standards and contained unsafe carcinogenic impurities. If you relied on Glenmark’s Carvedilol for your daily healthcare, you don’t stand alone in demanding full transparency and fair financial compensation.

If you currently take generic Carvedilol, it is critical that you consult your prescribing doctor or pharmacist before making any changes to your medication routine, as stopping a beta-blocker abruptly can lead to severe cardiovascular complications. You can check your prescription bottle label or ask your pharmacist to confirm whether your medication was manufactured by Glenmark Pharmaceuticals.